報價延遲最少15分鐘:2026/04/21 23:57 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.48 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.26/--
|
|
企業價值
39.91M
|
| 資產負債 |
|
每股賬面淨值
0.68
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drugproduct pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments. |
